134419-59-3

Basic information

• Product Name: Tetrahydro-2H-pyran-4-yl methanesulfonate
• Synonyms: Tetrahydro-2H-pyran-4-yl methanesulfonate;4-Tetrahydropyranyl Methanesulfonate, 95%;Tetrahydro-2H-pyran-4-ylmethanesulphonate;2H-Pyran-4-ol, tetrahydro-, methanesulfonate;oxan-4-yl methanesulfonate
• CAS NO: 134419-59-3
• Molecular Formula: C₆H₁₂O₄S
• Molecular Weight: 180.22
• Product Categories: Pyrans, Piperidines & Piperazines
• Mol File: 134419-59-3.mol
• Article Data: 60

Chemical Properties

• Boiling Point: 329.1 °C at 760 mmHg
• Flash Point: 152.8 °C
• Appearance: /
• Density: 1.26 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Dichlromethane, DMSO (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly)
• Stability: Moisture Sensitive
• CAS DataBase Reference: Tetrahydro-2H-pyran-4-yl methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: Tetrahydro-2H-pyran-4-yl methanesulfonate(134419-59-3)
• EPA Substance Registry System: Tetrahydro-2H-pyran-4-yl methanesulfonate(134419-59-3)

Safety Data

• Hazardous Substances Data: 134419-59-3(Hazardous Substances Data)

Usage

Uses

Tetrahydro-2H-pyran-4-yl Methanesulfonate is an intermediate in the synthesis of 3,4,5-Trimethoxy-2-nitro Acetophenone (T795510). 3,4,5-Trimethoxy-2-nitro acetophenone is an intermediate used to prepare substituted 4-alkyl-2(1H)-quinazolinones as potential cardiotonics. It can be also used as an intermediate to synthesize 2-Amino-3,4,5-trimethoxybenzophenones as potent tubulin polymerization inhibitors.

Upstream product

• 29943-42-8 Tetrahydro-4H-pyran-4-one 
• 108-97-4 4-pyrone 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 116312-69-7 tetrahydro-2H-pyran-4-yl-hydrazine 
• 1040377-02-3 4-bromo-1-(tetrahydro-2H-pyran-4-yl)- 1H-pyrazole 
• 1218916-45-0 3-(4-methylphenyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridine 
• 1097921-20-4 4-(3-methoxy-4-nitrophenoxy)tetrahydro-2H-pyran 
• 1097921-23-7 2-methoxy-4-(tetrahydro-pyran-4-yloxy)-phenylamine 
• 1233541-01-9 ethyl 2-{[4-{[6-(methylsulfonyl)pyridin-3-yl]oxy}-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]hydrazono}propanoate 
• 1233540-86-7 ethyl (2E)-2-{[4-({6-[(2-methoxyethoxy)methyl]pyridin-3-yl}oxy)-2-(tetrahydro-2H-pyran-4-yloxy)phenyl]hydrazono}propanoate 
• 1233540-85-6 4-({6-[(2-Methoxyethoxy)methyl]pyridin-3-yl}oxy)-2-(tetrahydro-2H-pyran-4-yloxy)aniline 
• 1233540-84-5 2-[(2-methoxyethoxy)methyl]-5-[4-nitro-3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]pyridine 
• 1233540-75-4 5-{[6-(methoxymethyl)pyridin-3-yl]oxy}-7-(tetrahydro-2H-pyran-4-yloxy)-1H-indole-2-carboxamide 
• 1233540-74-3 5-{[6-(methoxymethyl)pyridin-3-yl]oxy}-7-(tetrahydro-2H-pyran-4-yloxy)-1H-indole-2-carboxylic acid 
• 1233540-73-2 ethyl 5-{[6-(methoxymethyl)pyridin-3-yl]oxy}-7-(tetrahydro-2H-pyran-4-yloxy)-1H-indole-2-carboxylate 
• 1233541-00-8 4-{[6-(Methylsulfonyl)pyridin-3-yl]oxy}-2-(tetrahydro-2H-pyran-4-yloxy)aniline 
• 1233540-99-2 2-(methylsulfonyl)-5-[4-nitro-3-(tetrahydro-2H-pyran-4-yloxy)phenoxy]pyridine 

Relevant articles and documents

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.

AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.